Zhejiang Shapuaisi Pharmaceutical Co Ltd Working Capital to Net Assets Ratio
Zhejiang Shapuaisi Pharmaceutical Co Ltd working capital to net assets ratio. Zhejiang Shapuaisi Pharmaceutical Co Ltd (603168) has a Working Capital to Net Assets ratio of 3.5% as of September 2025. Working capital of CN¥56.85 Million (current assets of CN¥418.03 Million minus current liabilities of CN¥361.18 Million) is measured against net assets of CN¥1.62 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check 603168 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Zhejiang Shapuaisi Pharmaceutical Co Ltd (2008–2024)
Working capital to net assets ratio of Zhejiang Shapuaisi Pharmaceutical Co Ltd from 2008 to 2024. This chart shows how Zhejiang Shapuaisi Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 17 annual periods from 2008 to 2024. As of September 2025, the ratio stands at 3.5%, reflecting working capital of CN¥56.85 Million against net assets of CN¥1.62 Billion CNY. See 603168 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Zhejiang Shapuaisi Pharmaceutical Co Ltd Working Capital to Net Assets Ratio by Year (2008–2024)
Zhejiang Shapuaisi Pharmaceutical Co Ltd working capital to net assets ratio by year from 2008 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Zhejiang Shapuaisi Pharmaceutical Co Ltd from 2008 to 2024, covering 17 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see how large is Zhejiang Shapuaisi Pharmaceutical Co Ltd's balance sheet.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | -0.7% | CN¥-10.81 Million | CN¥1.59 Billion | CN¥366.67 Million | CN¥377.47 Million | ▼ -11.4 pp |
| 2023 | 10.7% | CN¥184.96 Million | CN¥1.73 Billion | CN¥552.66 Million | CN¥367.70 Million | ▼ -19.7 pp |
| 2022 | 30.4% | CN¥521.99 Million | CN¥1.72 Billion | CN¥727.80 Million | CN¥205.82 Million | ▲ +3.9 pp |
| 2021 | 26.5% | CN¥358.67 Million | CN¥1.35 Billion | CN¥553.95 Million | CN¥195.27 Million | ▲ +4.6 pp |
| 2020 | 21.9% | CN¥285.73 Million | CN¥1.31 Billion | CN¥647.65 Million | CN¥361.92 Million | ▼ -34.1 pp |
| 2019 | 56.0% | CN¥833.85 Million | CN¥1.49 Billion | CN¥929.83 Million | CN¥95.98 Million | ▲ +5.6 pp |
| 2018 | 50.4% | CN¥747.06 Million | CN¥1.48 Billion | CN¥911.47 Million | CN¥164.41 Million | ▲ +5.5 pp |
| 2017 | 45.0% | CN¥745.28 Million | CN¥1.66 Billion | CN¥957.40 Million | CN¥212.13 Million | ▲ +1.4 pp |
| 2016 | 43.6% | CN¥694.68 Million | CN¥1.59 Billion | CN¥942.56 Million | CN¥247.88 Million | ▲ +30.0 pp |
| 2015 | 13.6% | CN¥121.27 Million | CN¥891.62 Million | CN¥424.18 Million | CN¥302.91 Million | ▼ -37.6 pp |
| 2014 | 51.2% | CN¥390.30 Million | CN¥762.90 Million | CN¥486.44 Million | CN¥96.14 Million | ▲ +11.6 pp |
| 2013 | 39.6% | CN¥139.75 Million | CN¥353.31 Million | CN¥315.01 Million | CN¥175.26 Million | ▼ -10.6 pp |
| 2012 | 50.2% | CN¥137.64 Million | CN¥274.21 Million | CN¥299.96 Million | CN¥162.33 Million | ▼ -5.0 pp |
| 2011 | 55.2% | CN¥111.39 Million | CN¥201.95 Million | CN¥231.82 Million | CN¥120.43 Million | ▲ +7.8 pp |
| 2010 | 47.4% | CN¥72.04 Million | CN¥152.04 Million | CN¥142.49 Million | CN¥70.45 Million | ▲ +21.1 pp |
| 2009 | 26.3% | CN¥28.80 Million | CN¥109.67 Million | CN¥105.95 Million | CN¥77.15 Million | ▲ +12.5 pp |
| 2008 | 13.8% | CN¥12.88 Million | CN¥93.58 Million | CN¥82.11 Million | CN¥69.24 Million | — |